טוען...
Apatinib with etoposide capsules as a third- or further-line therapy for extensive-stage small cell lung cancer: an open-label, multicenter, single-arm phase II trial
BACKGROUND: Patients with extensive-stage small-cell lung cancer (ES-SCLC) have a particularly poor prognosis. And the treatment options for patients with relapsed or refractory ES-SCLC are limited. Thus, we conducted an open-label, multicenter, single-arm phase II clinical trial to assess the effic...
שמור ב:
| הוצא לאור ב: | Transl Lung Cancer Res |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
AME Publishing Company
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7947412/ https://ncbi.nlm.nih.gov/pubmed/33718030 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr-20-1235 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|